All News

infusion.biologic.jpg

Low Persistence of Biologics in Psoriatic Arthritis

Jack Cush, MD

A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients

Read Article
patient.safety.jpg

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Read Article
podcast logo

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.

Read Article
TB.EMimage.CDC_.jpg

Low Risk of TB with Secukinumab

Jack Cush, MD

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were f

Read Article
2020 Year Review

2020 Rheumatology Year in Review

Jack Cush, MD

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

Read Article
Xeljanz4.jpg

Delays in Diagnosis of Axial Spondyloarthritis

Jack Cush, MD

The diagnosis of axial spondyloarthritis (and anklylosing spondylitis) (axSpA) is often delayed and usually not diagnosed by rheumatologists; a recent metanalysis shows that longer delays were attributable to lower education levels, younger age at onset and absence of extra-articular manifes

Read Article
Low Persistence of Biologics in Psoriatic Arthritis A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients. https://t.co/CzQnpAnttW https://t.co/uYU778rwod

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie has released data from KEEPsAKE-1 and KEEPsAKE-2 studies (1407 pts) showing Risankizumab (IL--23 inhibitor) is effective in Psoriatic arthritis; RIS Rx pts achieved ACR20 of 57% and 51% at week 24 (vs PBO 34% and 27%; p<0.001) https://t.co/wPQMqLnhOO

Links:

Dr. John Cush RheumNow ( View Tweet)

Sign up for RheumNow Live, March 20 and 21st. CME credits available. https://t.co/uwxOVh142F https://t.co/GqkCLBGl62

Links:

Dr. John Cush RheumNow ( View Tweet)
Several studies have shown that Xray progression has lessened in recent yrs - presumeably from more aggressive Rx by Rheums! Still - Predictors of Xray long term damage = high ESR/CRP, baseline xray damage, -CCP/RF positivity https://t.co/2iaMiaquEV https://t.co/cgEP4QBvL4

Links:

Dr. John Cush RheumNow ( View Tweet)

SELECT-PsA2, UPA vs PLBO in refractory PsA, @ARD_BMJ Better ACR20 (57% vs 24% PLBO, NNT~3) and ACR50 (32% vs 5% PLBO, NNT~4). Decent PASI 90 (30% vs 6%, NNT~4) Similar adverse events to RA pop. Nice to have another option, esp in refractory dx! https://t.co/Zz2WYqswT2
Mike Putman EBRheum ( View Tweet)
Rheums: Got a Rheumatology question or case for RheumNow? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wzNmOzH4VE https://t.co/6w8CAAUkO6

Links:

Dr. John Cush RheumNow ( View Tweet)
The EMA has Approved AbbVie’s Upadacitinib (Rinvoq) in the EU for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis. https://t.co/H5E8dazQx4

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review (39 studies 152K patients) of comorbidities in Psoriatic arthritis; most common were HTN 34%, metabolic syndr 29%, obesity 27%, hyperlipidaemia 24% &CV Dz 19%. Comorbid pts: more severe dz, worse QOL & more drug discontinuation https://t.co/VxyYlPltDc

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish Armed Forces study suggests the least fit are at greatest risk for developing psoriasis later inlife. From 1968 -2005 1,886,542 military recruits were followed mean 31 yrs. Low CV fitness showed higher rate of psoriasis (HR 1.35) and PsA (HR 1.44) https://t.co/52zTjMM24y

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts. https://t.co/r5Cf4WS63s https://t.co/zN99Jo9bO0

Links:

Dr. John Cush RheumNow ( View Tweet)
Sign up to attend RheumNow Live--March 20 and 21. CME credits available https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d

Links:

Dr. John Cush RheumNow ( View Tweet)
2020 Rheumatology Year in Review-- Read our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond. https://t.co/QisCpdcLEa https://t.co/pZekUvcomE

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts. https://t.co/r5Cf4WS63s https://t.co/fEV77xMUye

Links:

Dr. John Cush RheumNow ( View Tweet)
National Psoriasis Foundation Task Force updated their COVID-19 guidance statements. Including Guidance 4.6, stating PsA pts who receive a mRNA-COVID vaccine should continue their biologic or oral therapies as they manag of their psoriatic disease https://t.co/byujtDET33

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×